



1 2 3 4 5 6




***FIG. 1***

1 2 3 4 5




***FIG. 2***


1 2 3 4 5 6



***FIG. 3***




***FIG. 4***




***FIG. 5***

FDCPmix proliferation inhibition by  
INPROL: direct effect *in vitro*



**FIG. 6**


**INPROL affects dynamic of CFU-S proliferation inhibition**



**FIG. 7**


**FIG. 8**

**INPROL injected *in vivo* protects mice  
from the lethal double 5FU treatment**






**Survival of I thally irradiated  
mice after treatment with INPROL**




***FIG. 9***

**Cell regeneration in BMLTC - L1210 cultures  
after combined AraC plus Inprol treatment**




***FIG. 10A***

**Cell regeneration in BMLTC - L1210 cultures  
after combined AraC plus Inprol treatment**




***FIG. 10B***

30 days radioprotection by the bone marrow cells  
after preincubation with (B) or without (A) INPROL




**FIG. 11**

**Marrow repopulating ability of BDF1  
mice cells after incubation with INPROL**




***FIG. 12***

**Pre-B progenitors number in Lymphoid Long Term Culture  
after preincubation with or without INPROL**




***FIG. 13***

INPROL improves the repopulating ability  
(LTC-IC number) of leukemic peripheral blood cells



**FIG. 14**


**FIG. 15A**



Analysis: Channel A

Peak No.	Time	Type	Height( $\mu$ V)	Area( $\mu$ Y-sec)	Area%
1	3.126	N1	691	7578	0.041
2	3.315	N2	1011	5150	0.027
3	49.618	N	8584	349227	1.893
4	51.298	N	1456	20274	0.109
5	52.673	N1	138069	2633395	14.278
6	53.148	N2	271587	14050458	76.181
	54.935	N3	33016	1332820	7.226
	67.595	N	3270	44507	0.241
TOTAL AREA				18443409	99.996





Analysis: Channel A

Peak No.	Time	Type	Height( $\mu$ Y)	Area( $\mu$ Y-sec)	Area%
1	4.383	N1	3945	95125	0.119
2	5.080	N2	28639	330889	0.413
3	5.216	N3	49084	531867	0.665
4	7.980	N1	399424	1110511	1.389
5	8.100	Err	1203320	2882013	3.605
6	8.241	N3	443249	1506159	1.884
7	8.386	N4	481563	2185702	2.734
8	8.533	N5	412886	1826165	2.284
9	8.701	N6	321500	842122	1.053
10	8.745	N7	404661	1610380	2.014
11	8.995	N8	435765	2489721	3.114
12	9.316	N9	517790	4801831	6.007

**FIG. 15B**




***FIG. 15C***

[illegible]

[illegible]


# FIG. 16C

hHemA.pep	1	V-LSPADKIN	10	VKAAWGKVGA	20	HA-GEYGAEA	30	LE-RMFLSFP	40	TTKTYFFPHF-	50
hHemB.pep	1	VHLTPEEKSA		VTALWGKV--		-NVDEVGGEA		LG-RLLVVYP		WTQRRFFESFG	50
mHemA.pep	1	V-LSGEDKSN		IKAAWGKIGG		HG-AEYGAEA		LE-RMFASFP		TTKTYFFPHF-	50
mHemB.pep	1	VHLTDAEKAA		VSCLWGKVNS		D---EVGGEA		L-GRLLVVYP		WTQRYFDSFG	50
pHemA.pep	1	V-LSAADKAN		VKAAWGKVGG		QA-GAHGAEA		LE-RMFLGFP		TTKTYFFPHF-	50
pHemB.pep	1	VHLSAEKEEA		VLGLWGKVNV		D---EVGGEA		L-GRLLVVYP		WTQRRFFESFG	50
hHemA.pep	51	DLSH-----G	60	SAQVKGHGKK	70	VADALTN---	80	AVAHVDDMPN	90	ALS--ALSDL	100
hHemB.pep	51	DLSTPDVAMG		NPKVKAHKK		VLGA---FSD		GLAHLNLKKG		TFA--TLSEL	100
mHemA.pep	51	DVSH-----G		SAQVKGHGKK		VADALAS---		AAGHLDDLPG		ALS--ALSDL	100
mHemB.pep	51	DLSSASAIMG		NAKVKAHKK		V---ITAFND		GLNHLDLKG		TFASL--SEL	100
pHemA.pep	51	NLSH-----G		SDQVKAHKK		VADALTK---		AVGHLDDLPG		ALS--ALSDL	100
pHemB.pep	51	DLSNADAVMG		NPKVKAHKK		V---LQSFSD		GLKHLNLKKG		TFAKL--SEL	100
hHemA.pep	101	HAHKLVRVDPV	110	NFKLLSHCLL	120	VTLAHLPAE	130	FTPAVHASLD	140	-KFLASVSTV	150
hHemB.pep	101	HCDKLHVDPE		NFRLLGNVLV		CVLAHHFGKE		FTPPVQAAVQ		-KVVAGVANA	150
mHemA.pep	101	HAHKLVRVDPV		NFKLLSHCLL		VTLASHHPAD		FTPAVHASLD		-KFLASVSTV	150
mHemB.pep	101	HCDKLHVDPE		NFRLLGNMIV		IVLGHHLGKD		FTPAAQAAF-		QKVVAGVATA	150
pHemA.pep	101	HAHKLVRVDPV		NFKLLSHCLL		VTLAHHHPDD		FNPSVHASLD		-KFLANVSTV	150
pHemB.pep	101	HCDQLHVDPE		NFRLLGNVIV		VVLARRLGH		FNPDVQAAF-		QKVVAGVANA	150
hHemA.pep	151	LTSKYR....	160	.....	170	.....	180	.....	190	.....	200
hHemB.pep	151	LAHKYH....		.....		.....		.....		.....	200
mHemA.pep	151	LTSKYR....		.....		.....		.....		.....	200
mHemB.pep	151	LAHKYH....		.....		.....		.....		.....	200
pHemA.pep	151	LTSKYR....		.....		.....		.....		.....	200
pHemB.pep	151	LAHKYH....		.....		.....		.....		.....	200




Analysis Channel A

Peak No.	Time	Type	Height( $\mu$ Y)	Area ( $\mu$ Y-sec)	Area %
1	48.200	N	1677	20438	1.515
2	52.076	N1	7625	116393	8.631
3	52.510	N2	32010	881490	65.369
4	53.660	N3	10066	330153	24.483
Total Area				1348474	99.998




Analysis Channel A


Peak No.	Time	Type	Height( $\mu$ Y)	Area ( $\mu$ Y-sec)	Area %
1	47.110	N1	1727	24840	0.204
2	47.723	N2	75067	1738939	14.321
3	49.153	N3	188795	6206410	51.114
4	52.250	N1	81476	3046748	25.092
5	52.115	N2	13195	202166	1.664
6	53.613	N3	19211	914954	7.535
	65.753	N	818	8066	0.066
Total Area				12142123	99.996



***FIG. 18***



***FIG. 19A***



***FIG. 19B***



**FIG. 20**

Comparison of Inprol and Hemoglobin Chains in FDP-Cmix Assay





FIG. 21






FIG. 22A




FIG. 22B





FIG. 22C



*FIG. 23*